Impact of the COVID-19 Pandemic on Medical Oncology Workload: A Provincial Review.


Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
07 03 2023
Historique:
received: 03 02 2023
revised: 24 02 2023
accepted: 03 03 2023
medline: 30 3 2023
entrez: 28 3 2023
pubmed: 29 3 2023
Statut: epublish

Résumé

(1) Background: Cancer is the leading cause of death in Canada, with significant resource limitation impacting the delivery of cancer care nationwide. The onset of the COVID-19 pandemic forced additional resource restriction and diversion, further impacting care delivery. Our intention is to analyze the impact COVID-19 on a provincial medical oncology workload and bring attention to the limitations of the current workload metric for oncologists. (2) Methods: All medical oncology patient encounters were extracted and compared, collected by year and encounter type, from April 2014 through March 2022. (3) Results: There was an increase in all patient encounters by an average of 9.5% per year, including during the strictest COVID-19 restrictions. There was an increase in virtual care encounters from 37.9% to 52.1%. (4) Conclusions: Medical Oncology workloads have increased over time and estimates suggest growing demand. Little data exist to inform workforce requirements and actual workload is not captured by the current metric. Though volume of new consults continues to increase, COVID-19 has highlighted additional changes in the delivery of care, likely with lasting impact, little of which are included in the current workload metric.

Identifiants

pubmed: 36975451
pii: curroncol30030238
doi: 10.3390/curroncol30030238
pmc: PMC10047010
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

3149-3159

Références

J Oncol Pract. 2018 Jul;14(7):e438-e445
pubmed: 29996073
J Oncol Pract. 2014 Jan;10(1):26-31
pubmed: 24443731
J Glob Oncol. 2018 Sep;(4):1-11
pubmed: 29244632
Clin Ther. 2017 Nov;39(11):2125-2134
pubmed: 28939405
J Thorac Oncol. 2022 Jul;17(7):931-936
pubmed: 35489693
Int J Cancer. 2022 Apr 15;150(8):1244-1254
pubmed: 34843106
Curr Oncol. 2018 Jun;25(3):206-212
pubmed: 29962838
Radiother Oncol. 2012 Apr;103(1):123-9
pubmed: 22296747
Curr Oncol Rep. 2022 Jul;24(7):917-927
pubmed: 35347594
Curr Oncol. 2020 Dec 31;28(1):233-251
pubmed: 33704191
CMAJ. 2022 May 2;194(17):E601-E607
pubmed: 35500919
Clin Oncol (R Coll Radiol). 2020 Jan;32(1):e19-e26
pubmed: 31324474
Future Oncol. 2020 Nov;16(33):2687-2690
pubmed: 32815421
Clin Transl Oncol. 2012 Jun;14(6):423-9
pubmed: 22634530
ESMO Open. 2020 Oct;5(5):e000880
pubmed: 33051192
Cancers (Basel). 2021 Jan 09;13(2):
pubmed: 33435389

Auteurs

Margaret Sheridan (M)

Division of Medical Oncology, Department of Medicine, Nova Scotia Health and Dalhousie University, Halifax, NS B3H 2Y9, Canada.

Bruce Colwell (B)

Division of Medical Oncology, Department of Medicine, Nova Scotia Health and Dalhousie University, Halifax, NS B3H 2Y9, Canada.

Nathan W D Lamond (NWD)

Division of Medical Oncology, Department of Medicine, Nova Scotia Health and Dalhousie University, Halifax, NS B3H 2Y9, Canada.

Robyn Macfarlane (R)

Division of Medical Oncology, Department of Medicine, Nova Scotia Health and Dalhousie University, Halifax, NS B3H 2Y9, Canada.

Daniel Rayson (D)

Division of Medical Oncology, Department of Medicine, Nova Scotia Health and Dalhousie University, Halifax, NS B3H 2Y9, Canada.

Stephanie Snow (S)

Division of Medical Oncology, Department of Medicine, Nova Scotia Health and Dalhousie University, Halifax, NS B3H 2Y9, Canada.

Lori A Wood (LA)

Division of Medical Oncology, Department of Medicine, Nova Scotia Health and Dalhousie University, Halifax, NS B3H 2Y9, Canada.

Ravi Ramjeesingh (R)

Division of Medical Oncology, Department of Medicine, Nova Scotia Health and Dalhousie University, Halifax, NS B3H 2Y9, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH